FLATEXDEGIRO-AG
Oliver Behrens appointed as new Chief Executive Officer (CEO)
flatexDEGIRO AG (the “Company”), one of the leading and fastest growing online brokers in Europe, announces that the Company’s Supervisory Board has appointed Oliver Behrens (60) as Chief Executive Officer (CEO) of flatexDEGIRO AG, effective from October 1, 2024, for a duration of three years. Furthermore, Oliver Behrens will also take over as CEO of flatexDEGIRO Bank AG.
Oliver Behrens brings 40 years of experience in the European financial industry with a strong link to brokerage and an outstanding network in international finance and politics.
From 2015 to June 2024, Oliver Behrens lately was CEO of Morgan Stanley Europe Holding SE, Morgan Stanley Europe SE and Morgan Stanley Bank AG, Frankfurt am Main, as well as Member of the Board of Morgan Stanley International Limited, London. Moreover, until 2014, he also served as Member of the Board of Deka-Bank for nine years, lately as Deputy CEO. From 1992 to 2005, he worked in Frankfurt and Luxembourg, among others, across various functions in the former DWS Group, DWS and Deutsche Asset Management, where he was lately Spokesman of the Management Board of Deutsche Asset Management Investment GmbH. Since June 2024, Oliver Behrens is Chairman of DWS Group GmbH & Co. KGaA’s Supervisory Board.
Oliver Behrens takes over from Dr Benon Janos (52) and Stephan Simmang (58), who, since May 1, 2024, serve as interim Co-CEOs of the Company, in addition to their existing responsibilities as CFO and CTO, respectively.
On his appointment as new CEO of flatexDEGIRO AG, Oliver Behrens commented: "The European online brokerage business is still in its early innings, holding enormous potential for growth and value enhancement. Together with flatexDEGIRO’s strong leadership team, I am very much looking forward to leading the company into the next phase of its evolution, further enhancing the investment experience for millions of clients across 16 countries while firmly establishing flatexDEGIRO as the driving force in the European online brokerage market.”
Martin Korbmacher, Chairman of flatexDEGIRO’s Supervisory Board, said: “With Oliver Behrens, we have succeeded in engaging a real heavyweight of the European financial industry for this leading role at flatexDEGIRO. It fills us with pride and speaks for the great potential of flatexDEGIRO that we have been able to recruit an executive of his caliber for the vacant CEO position. With his outstanding industry experience and his strong, team-orientated leadership personality, Oliver Behrens is a real gain, both operationally and organizationally, for our company which he already knows very well from the long-standing and cooperative business relationships with his previous employer.”
The appointment of Oliver Behrens as CEO of flatexDEGIRO AG and flatexDEGIRO Bank AG is subject to customary approvals by the German Federal Financial Supervisory Authority (BaFin).
Appointment of Dr Benon Janos (CFO) as Deputy CEO
Moreover, the Company’s Supervisory Board has appointed Dr Benon Janos (CFO) as Deputy CEO of flatexDEGIRO AG, effective from October 1, 2024. Dr Benon Janos will also fulfil this function at flatexDEGIRO Bank AG.
Contract extension of Dr Benon Janos (Deputy CEO & CFO) and Stephan Simmang (CTO) until mid-2029
Furthermore, the Supervisory Board of flatexDEGIRO has also decided to extend the Management Board contracts of Dr Benon Janos (Deputy CEO & CFO) and Stephan Simmang (CTO) until May 31, 2029. Dr Benon Janos and Stephan Simmang have held management positions at flatexDEGIRO since 2016, serving as members of the Company’s Management Board since 2023.
Therefore, effective from October 1, 2024, flatexDEGIRO AG’s Management Board will consist of four members, namely Oliver Behrens (CEO), Dr Benon Janos (Deputy CEO & CFO), Stephan Simmang (CTO) and Christiane Strubel (CHRO).
Martin Korbmacher, Chairman of flatexDEGIRO’s Supervisory Board, said: “On behalf of the whole Supervisory Board, I would like to express our deepest gratitude to Dr Benon Janos and Stephan Simmang for stepping up and taking on additional responsibilities as Co-CEOs during the past months, ensuring a professional and orderly transition after the departure of the former CEO. The Supervisory Board is very much looking forward to extending the great collaboration over the coming years and expressly thanks Dr Benon Janos and Stephan Simmang for their leadership and integrity, especially during this critical transition phase.”
About flatexDEGIRO AG
flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR) operates one of the leading and fastest growing online brokerage platforms in Europe. Based on modern, in-house state-of-the-art technology, customers of the flatex and DEGIRO brands are offered a wide range of independent products with execution on top TIER 1 exchanges. The technological edge, high efficiency and strong economies of scale enable flatexDEGIRO to continuously improve its service offering for clients and set leading standards in terms of product, price and platform quality.
With around 3 million customer accounts and around 60 million securities transactions processed in 2023, flatexDEGIRO is one of the largest retail online brokers in Europe. In times of bank consolidation, low real interest rates and digitalization, flatexDEGIRO is ideally positioned for further growth.
Further information can be found at https://www.flatexdegiro.com/en.
| Language: | English | |
| Company: | flatexDEGIRO AG | |
| Omniturm, Große Gallusstraße 16-18 | ||
| 60312 Frankfurt / Main | ||
| Germany | ||
| Phone: | +49 (0) 69 450001 0 | |
| E-mail: | ir@flatexdegiro.com | |
| Internet: | www.flatexdegiro.com | |
| ISIN: | DE000FTG1111 | |
| WKN: | FTG111 | |
| Indices: | SDAX | |
| Listed: | Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Munich, Stuttgart, Tradegate Exchange |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828514871/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK™,a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press release
- ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies - - In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV1 and further decreased sweat chloride compared to TRIKAFTA® - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and t
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press release
- Approximately 300 more people with cystic fibrosis in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
Andersen Global udvider sin ekspertise med tilføjelsen af Valora20.12.2024 17:07:00 CET | Pressemeddelelse
Andersen Global fortsætter sin udvidelse af servicetilbud gennem en samarbejdsaftale med Valora, der er en uafhængig virksomhed med speciale i levering af skræddersyede løsninger til både private og institutionelle kunder globalt. Valora har kontorer i Miami og Raleigh og desuden global tilstedeværelse i Den Dominikanske Republik, Storbritannien og Caymanøerne. Valora blev grundlagt i 2011 af partneren Luis de Leon og tilbyder et stort udvalg af tjenester, blandt andet værdiansættelse, performance, regnskab og administration, global enhedsstyring, fondsvirksomhed og andre skræddersyede løsninger. "Et samarbejde med Andersen passer godt til både vores kunder og vores team," siger Luis. "Synergierne mellem for vores servicetilbud vil sætte os i stand til at levere omfattende og integrerede løsninger med stadigt stigende global rækkevidde." Global Chairman og CEO for Andersen Mark L. Vorsatz udtaler: "Valoras team og virksomhedskultur er, sammen med deres fokus på det praktiske, et godt m
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom